Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]MLN6907
- Development stage
- Phase 1
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]MLN6907 is a radiopharmaceutical diagnostic imaging agent developed by Millennium Pharmaceuticals (a subsidiary of Takeda). It is a Gallium-68 labeled tracer designed for Positron Emission Tomography (PET) imaging. The agent specifically targets Guanylate Cyclase 2C (GUCY2C), a transmembrane receptor protein that is normally expressed in the intestinal epithelium but is frequently overexpressed in primary and metastatic colorectal carcinoma (mCRC). By binding to GUCY2C, [68Ga]MLN6907 allows for the non-invasive detection and localization of metastatic lesions, such as liver metastases, and can be used to evaluate GUCY2C expression levels to identify patients who may benefit from GUCY2C-targeted therapeutic agents.
- Other names
- gallium Ga 68-labeled MLN6907[68Ga]MLN6907Gallium-68-MLN-6907Gallium68-MLN-6907Gallium 68-MLN-6907[68Ga]DOTA-MLN6907
02
Targets
GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on [68Ga]MLN6907.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]MLN6907.